GFM
RAPP

GF Fund Management’s Rapport Therapeutics RAPP Stock Holding History

GF Fund Management’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.1K Sell
1,011
-59
-6% -$2.17K ﹤0.01% 407
2026
Q1 		$33.5K Buy
1,070
+135
+14% +$3.8K ﹤0.01% 448
2025
Q4 		$28.4K Buy
935
+146
+19% +$4.04K ﹤0.01% 470
2025
Q3 		$23.4K Sell
789
-147
-16% -$2.62K ﹤0.01% 474
2025
Q2 		$10.6K Hold
936
– – ﹤0.01% 565
2025
Q1 		$9.39K Buy
936
+168
+22% +$2.18K ﹤0.01% 574
2024
Q4 		$13.6K Buy
+768
New +$17K ﹤0.01% 507

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

GF Fund Management's RAPP Position: Q2 2026 in Review

GF Fund Management reduced its Rapport Therapeutics (RAPP) stake by 5.5% in Q2 2026, selling an estimated $2.17K and leaving 1,011 shares worth $42.1K. The position accounts for ﹤0.01% of the portfolio, ranked #407.

GF Fund Management first reported a position in RAPP in Q4 2024 and has held it in 7 quarters since. 161 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • GF Fund Management held 1,011 shares of Rapport Therapeutics worth $42.1K as of Q2 2026.
  • GF Fund Management sold 59 Rapport Therapeutics shares in Q2 2026, an estimated $2.17K.
  • Rapport Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #407 holding.
  • GF Fund Management first reported a position in Rapport Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 161 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.